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Abstract
Spatial and temporal concentration gradients of chemoattractants direct many biological processes,
especially the guidance of immune cells to tissue sites during homeostasis and responses to
infection. Such gradients are ultimately generated by secretion of attractant proteins from single
cells or collections of cells. Here we describe cell-sized chemoattractant-releasing polysaccharide
microspheres, capable of mimicking chemokine secretion by host cells and generating sustained
bioactive chemokine gradients in their local microenvironment. Exploiting the common
characteristic of net cationic charge and reversible glycosaminoglycan binding exhibited by many
chemokines, we synthesized alginate hydrogel microspheres that could be loaded with several
different chemokines (including CCL21, CCL19, CXCL12, and CXCL10) by electrostatic
adsorption. These polysaccharide microspheres subsequently released the attractants over periods
ranging from a few hrs to at least 1 day when placed in serum-containing medium or collagen gels.
The generated gradients were able to attract cells more than hundreds of microns away to make
contact with individual microspheres. This versatile system for chemoattractant delivery could
find applications in immunotherapy, vaccines and fundamental chemotaxis studies in vivo and in
vitro.
1. Introduction
Directed lymphocyte trafficking is a key part of development, homeostasis and ongoing
immune responses within primary lymphoid organs, secondary lymphoid organs, and
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peripheral tissues. The migration of lymphocytes is controlled in part by a family of host
chemotactic molecular signals, chemokines [1–4]. Chemokines are secreted by host cells
and diffuse into the surrounding tissue to establish soluble and/or immobilized concentration
gradients [5]. These attractants are also displayed on the surfaces of endothelial cells at sites
of inflammation and on blood vessels in lymphoid organs, providing a key signal for arrest
of leukocytes on the endothelial wall for entry into tissues from the blood [5, 6].
Lymphocytes expressing cognate chemokine receptors sense concentration differences
within tissues and migrate up the gradient toward areas of high chemokine concentration [7],
a process called chemotaxis. Chemokines can also trigger chemokinesis, non-directed
migration stimulated by chemokines present at stimulatory levels without the presence of
functional spatial gradients [8, 9].
Through an understanding of fundamental principles of leukocyte trafficking, a variety of
therapeutic applications are being developed, such as vaccine adjuvants, anti-tumor reagents,
and anti-inflammatory treatments [10]. In vaccination and cancer therapy, a promising
approach is to locally engineer chemokine gradients with the goal of drawing immune cells
to tumors or immunization sites. For example, DNA or vaccinia virus vaccines co-injected
with DNA plasmids encoding the chemokines CCL21 or CCL19 increased the protective
immune response against Herps Simplex Type 1 Virus [11]. Intratumoral injection of
leukocyte-attracting recombinant chemokines, such as CCL21 [12] or CCL16 [13], have
shown promising anti-tumor effects. Intratumoral injection of dendritic cells transfected to
express CCL21 [14] or including CCL21 retroviral particles in adoptive T-cell therapy [15]
have shown improved effects in tumor rejection. The adenoviral delivery of CCL16
synergized with the use of CpG and anti-IL-10 antibody [16] to promote the accumulation of
dendritic cells and macrophages at tumor sites and elicited cascading innate and adaptive
immune responses to reject large tumors. Biomaterials may have a key role to play in this
setting, by providing the means to gain greater control over engineered chemoattractant
gradients relative to transfected cells or bolus attractant injection. Kumamoto et al. showed
that implanted poly(ethylene-co-vinyl acetate) rods releasing the mature dendritic cell
chemoattractant CCL19 and a tumor antigen could elicit promising anti-tumor immunity
[17]. The immature dendritic cell chemoattractant CCL20 has also been encapsulated in
biodegradable in situ-crosslinking hydrogels comprised of Dextran vinyl sulfone and
reactive polyethylene glycol [18] to attract antigen presenting cells to an injection site during
vaccination. Controlled release materials also offer the potential to engineer gradients for
basic studies of chemotaxis in vitro, such as demonstrated by Kress et al. who used optical
tweezer manipulation of attractant-releasing PLGA microspheres as a strategy to finely
position attractant gradients relative to responding cells [19].
We previously reported the use of poly (lactide-co-glycolide) (PLGA) microspheres loaded
with the chemokine CCL20 or bacterial formyl peptides to generate local dendritic cell
chemoattractant gradients [20]. This system was attractive as it employed a well-established
fully bioresorbable material for chemokine release, but the loading of chemokines (typical of
many protein cargos in PLGA particles) was limited to on the order of ~1 wt% of the
microspheres, and we found that obtaining functional release of many other candidate
chemokines of interest was problematic, likely due to the harsh microenvironment within
eroding PLGA particles [21–23]. Thus, we searched for an alternative system that could
more efficiently entrap chemokines with higher net bioactivity, and provide “point-source”
release of a broader range of attractants to engineer chemokine gradients in vitro and in vivo.
Apropos of this challenge, we recently developed injectable formulations of the well-known
anionic polysaccharide biomaterial alginate, based on mixing alginate aqueous solutions
with suspensions of calcium alginate microspheres; the microspheres served as local sources
of excess calcium that crosslinked the surrounding solution over a period of minutes via ion
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exchange [24, 25]. The favorable in vivo properties of these alginate materials and the
structural similarities of alginate to native glycosaminoglycans (GAGs) led us to
hypothesize that alginate microspheres could be utilized not only as ion reservoirs, but also
as carriers for reversible loading and controlled release of chemokines. Chemokines are
generally cationic small proteins (~8–20 KDa), which bind to GAGs in the extracellular
matrix (ECM) or on the surface of cells. Many chemokines bind the sulfated and carboxylic
acid residues of heparan sulfate (HS) and its analogs, in some cases with nM affinity, and
proteoglycan binding has been formally shown to be essential for the in vivo activity of
some chemokines [26–28]. We reasoned that similar interactions between chemoattractants
and acid groups of alginate microspheres would enable loading/release of chemokines, and
the ubiquitous nature of charge-mediated chemokine binding to matrix would allow this
approach to be applied to many host attractants. Providing support for this concept, alginate
has been used to encapsulate many therapeutic proteins via ionic interactions, such as basic
fibroblast growth factor (bFGF) [29], transforming growth factor-β1 (TGF-β1) [30], nerve
growth factor (NGF) [31], and platelet-derived growth factor (PDGF) [32].
Here, we report on studies testing this hypothesis and demonstrating a simple approach to
create chemokine-loaded microspheres that potently chemoattract immune cells. We
evaluated loading/release of several chemokines important in immunity, including CCL19,
CCL21, CXCL12 and CXCL10. We employed simulations of the gradient field generated
around individual microspheres coupled with Boyden chamber assays and direct
videomicroscopy imaging of human leukocytes migrating near alginate microspheres to test
the functionality of these attractant particles, and defined conditions for long-lived and long-
ranged attraction of human T-cells or dendritic cells to isolated microspheres or collections
of particles.
2. Materials and methods
2.1. Materials
LF120M alginates (70–150 mPa·s with 45–55% guluronic acid units) were obtained from
FMC Biopolymers (Sandvika, Norway). 2,2,4-Trimethylpentane (iso-octane, ChromAR,
99.5%) was obtained from Mallinckrodt Baker (Phillipsburg, NJ). Calcium chloride
dehydrate, Sorbitane monooleate (Span 80), Tween 80, HEPES buffer, and
lipopolysaccharide (LPS) from Escherichia coli, lectin from Phaseolus Vulgaris (PHA)
were purchased from Sigma–Aldrich (St. Louis, MO). Bovine type I collagen (PureCol®
stock solutions ~3 mg/ml) was obtained from Advanced Biomatrix (Tucson, Arizona).
Human recombinant CCL21, CCL19, CXCL12, GM-CSF and detection ELISA Duoset®
kits were purchased from R&D systems (Minneapolis, MN). Mouse CXCL10 and human
IL-4 recombinant proteins were obtained from Peprotech (Rocky Hill, NJ) and mouse
CXCL10 detection ELISA kits were purchased from R&D systems. Human recombinant
IL-2 was obtained from Chiron (Emeryville, CA). RPMI-glutamax, Alexa fluor 488 and
Alexa fluor 555 small scale labeling kits were purchased from Invitrogen (Carlsbad, CA).
Polydimethylsiloxane (PDMS) rubber culture chambers were cast from Sylgard 184 silicone
elastomer kits (Dow Corning, Midland, MI). Low autofluorescence phenol red-free RPMI
powder was obtained from Mediatech (Manassas, VA). Ficoll-paque for lymphocyte
isolation was purchased from GE Healthcare (Uppsala, Sweden). All materials were used as
received unless otherwise noted.
2.2. Synthesis of alginate microspheres
Alginate microspheres were synthesized using a procedure we previously reported [24, 25]:
Briefly, alginate was dissolved in phosphate buffered saline (PBS) pH 7.4 (1% wt/vol) and
passed through a sterile 0.45 μm syringe filter. The solution (400 μl) was added dropwise
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and homogenized at 25°C for 3 min at 8000 rpm (UltraTurrax T25 homogenizer, IKA
Works) in 35 ml of iso-octane containing 1.5 ml Span 80 and 0.5 ml Tween 80, and then 25
μl CaCl2 (5% wt/vol) solution was added dropwise followed by 4 min homogenization. The
resulting calcium alginate microspheres were collected by centrifugation and washing 2X
with 35 ml iso-octane followed by washing 3X with 1 ml deionized water, then stored at a
stock concentration of 5×106 microspheres/ml in deionized water at 4°C until use.
2.3. Characterization of microspheres
The size distributions of alginate microspheres in deionized water were determined using a
Horiba laser scanning particle size distribution analyzer LA-950V2. The morphology of
alginate microspheres was characterized using a Zeiss Axiovert 200 epi fluorescence
microscope, and the number concentration of alginate microspheres was quantitated via a
haemocytometer.
2.4. Loading of chemokines in alginate microspheres
To determine the net surface charge of candidate chemokines, crystal structures of
chemokines available from the Protein Data Bank were inspected (www.pdb.org, structures:
CXCL12: 2KED; CXCL10:1LV9) using Star Biochem software (MIT, Cambridge, MA) to
identify surface-exposed residues. For CCL21 and CCL19 whose crystal structures are not
yet available, it was assumed that all charged residues were exposed on the surface,
consistent with many other chemokines [33]. The isoelectric point of the chemoattractants
was calculated based on the published amino acid sequence.
Before use, chemokine was loaded into the alginate microspheres by adsorption: alginate
particle suspensions were spun down, the supernatant discarded, and the particles were
resuspended in a concentrated chemokine solution at 5×106 particles/ml (equivalent to 0.04
mg/ml alginate) for 90 min (except where otherwise noted) on a rotator at 4°C. Chemokine
stock solutions were diluted in PBS with 0.1 wt% BSA for these loading incubations. After
the incubation period, the microspheres were washed 3X with 1 ml phenol red-free RPMI
1640 medium containing 10% fetal calf serum (FCS) to remove unbound chemokine. The
chemokine-loaded particles were then resuspended in phenol red-free RPMI at 5×106
particles/ml and used for release or imaging studies. The amount of chemokine loaded was
evaluated by subtracting the quantity of chemokine detected in the washing supernatant
(analyzed by ELISA) from the total amount of attractant initially added in the loading
process. We confirmed that this analysis gave similar results to measurements obtained by
digesting microspheres with alginate lyase (10 ng/ml alginate lyase for 20 min at 37 °C) and
measuring the loaded chemokine directly.
2.5. Release of chemokines from alginate microspheres
Kinetics of chemokine release from the microspheres were determined by suspending 5×104
chemokine-loaded alginate microsphere in 1 ml releasing buffer (as noted in the text) and
incubating at 37 °C on an orbital shaker (200 rpm). At each time-point, the particles were
pelleted, the supernatant collected for analysis, and fresh buffer was added to approximate
sink conditions during release. The amount of chemokine in supernatant samples was
measured by ELISA.
In order to simulate the gradient fields developing around individual microspheres in our
chemotaxis assays, we calculated the apparent diffusion constant for chemokine within
individual alginate microspheres. This effective diffusivity, Deff, was determined by fitting
the measured fraction of chemokine released at each time-point using a short term solution
for Fick’s Second Law applied to spherical geometry in sink conditions (valid for time-
points when < 40% of the total release has occurred) [34]:
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where Mt is the amount of chemokine release at time t, M∞ is the total amount released at
infinite time (i.e. total amount loaded in the particles), and wi is the weight fraction of
microspheres with radius Ri, summed over the distribution of all microsphere sizes. This
analysis accounted for the polydispersity of the microspheres and the sum over all particle
sizes was carried out using the experimentally determined size distribution of the particles.
Data was fit using the built-in nonlinear regression algorithm of Prism 5.0 software
(GraphPad Software).
2.6. Cells
Peripheral blood mononuclear cells (PBMCs) were isolated by ficoll gradient centrifugation
of whole blood or unpurified buffycoats from healthy anonymous donors (Research Blood
Components, Boston, MA). Resting T-cells were isolated by magnetic sorting (pan human
T-cell negative selection kit, Miltenyi, Auburn, CA) and cultured in RPMI-glutamax
(Invitrogen, Carlsbad, CA) containing 10 mM HEPES and 10% FCS for 18 hr prior to use.
Activated T-cells were prepared by culturing PBMCs at 7×106 cells in 3 ml RPMI medium
with 10% FCS and stimulated with 1 μg/ml PHA for two days. On day 3, activated PBMCS
were ficolled to remove dead cells, followed by magnetic sorting using T-cell isolation kit
from Miltenyi. The purified human T-cells were cultured at 1×106/ml in 10% FCS
containing RPMI medium with 100 U/ml IL-2 and used on day 4. To prepare monocyte-
derived human dendritic cells (DCs), monocytes were isolated from PBMCs by magnetic
selection (CD14 microbead positive selection kit, Miltenyi) and then cultured at 1×106 cells/
ml in RPMI medium containing 25 ng/ml recombinant human IL-4 and 100 ng/ml
recombinant human GM-CSF for 7 days to generate monocyte-derived DCs. Medium was
changed every other day; on day 5, 100 ng/ml LPS was added to mature the DCs, and the
cells were used for experiments on day 7. Activated human T-cells or dendritic cells used
for imaging were labeled with 3.3 μM CMTPX (Invitrogen) prior to experiments according
to the manufacturer’s instructions.
2.7. Preparation of collagen hydrogels
Soluble collagen (3.0 mg/ml stock acid solution) was mixed with 0.1 M sterile NaOH and
10X phenol red-free RPMI in a 8:1:1 vol ratio to achieve pH 7.2, then this mixture was
combined with FCS (final conc. 10% vol/vol) and phenol red-free RPMI at a ratio of
3:0.33:0.67 to obtain a final collagen concentration of 1.8 mg/ml. This collagen precursor
solution was mixed with cells and/or alginate microspheres at desired concentrations and
incubated at 37°C to allow polymerization of the solution into a fibrillar collagen gel
containing the desired concentration of suspended cells and alginate particles.
2.8. Modified Boyden chamber chemotaxis assay
T-cells (5×104 cells in 50 μl) in RPMI medium with 10% FCS or 1.8 mg/ml collagen
solution were applied to the top compartment of 96-well polycarbonate filter plates with 5
μm pore sizes (Neuro Probe, Gaithersburg, MD); recombinant chemokines or chemokine-
loaded alginate microspheres in RPMI with 10% FCS (30 μl) were added to the lower
compartments of each chamber. CCL21-loaded alginate microspheres (2.5 μg/mg alginate)
were 10X serial diluted from 5×106 particles/ml (total CCL21 loaded on alginate
microsphere was equivalent to 10 μg/ml soluble CCL21) to generate dose titrations. After a
2 or 4 hr incubation at 37°C for cells added in medium or collagen, respectively, cells
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remaining on top of the filters were removed by gentle washing and those that migrated to
the bottom chamber were quantified using a Cyquant cell enumeration kit (Invitrogen)
following the manufacturer’s instructions.
2.9. Microsphere depot videomicroscopy chemotaxis assay
Custom culture wells composed of two interconnected cylindrical wells each ~4.5 mm in
diameter and ~3 mm in depth were prepared by sealing PDMS rubber molds against #1
borosilicate glass coverslip labtek chamber slides (Nalge Nunc Labtek). Collagen precursor
solution (30 μl) mixed with 5×104 alginate particles loaded with 0.8 μg CCL21 (50% was
Alexa fluor 488-labeled) was deposited in one chamber of the PDMS mold and incubated at
37°C for 5 min, then 30 μl of collagen mixed with CMTPX-labeled LPS-matured dendritic
cells at 1×106 cells/ml was deposited in the adjoining chamber. The labtek slide was
immediately placed in a 5% CO2, 37°C humidified environmental chamber on a Zeiss
Axiovert 200 inverted fluorescence microscope. Samples were imaged in time-lapse,
employing a computer-controlled robotic stage to collect images of 9 adjacent 334 × 448 μm
fields of view at 20X across the interface between the chemokine-loaded well and cell-
loaded well in rapid succession. Brightfield, green and red fluorescence images were
collected from all 9 fields every 5 min for 10 hrs.
2.10. Isolated microspheres videomicroscopy chemotaxis Assay
Single custom culture wells containing one cylindrical well (~ 4.5 mm in diameter and ~3
mm in depth) were sealed to glass coverslip imaging chambers similarly as described in 2.9.
Collagen precursor solution (30 μl) mixed with activated CMTPX-labeled human T-cells
(final conc., 3×106 cells/ml) and chemokine-alginate microspheres (final conc., 1×104
particles/ml) was deposited into the pre-heated culture well and then imaged in time-lapse.
One 334 × 448 μm field containing a single alginate microsphere was selected for imaging
in time-lapse in each sample. Brightfield and red fluorescence images were taken every
minute for 3 to 6 hrs.
2.11. Isolated microsphere chemokine gradient modeling
The release of chemokines and development of concentration gradient fields around
individual alginate microspheres embedded in collagen hydrogels was simulated by solving
Fick’s second law of diffusion for a single attractant-releasing microsphere centered in a
cubic space of dimension a using the transport of diluted species module in COMSOL
modeling software (COMSOL Inc., Burlington, MA). The dimension of the space, a, was
taken as the mean distance between microspheres dispersed within a collagen matrix at a
total number concentration CMS:
The COMSOL model solved differential equations for diffusion of chemokine with an initial
uniform concentration of attractant in the beads (Co) at time zero and no flux at the
boundaries:
where Dc is the diffusivity of chemokine in collagen and Deff is the effective diffusivity of
chemokine within the alginate microsphere, defined from our experimental measurements as
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described in section 2.5 above. Following prior work [20], because the porosity of the
fibrillar collagen matrix is on length scales much greater than the size of the chemokine and
we found no evidence for interactions of the chemokines studied with the type I collagen
used here in ELISA binding assays (data not shown), Dc was taken as half the diffusivity of
chemokine in water, Do. Do was estimated using the empirical relationship [35, 36]:
where A is a constant, 2.82×10−5 cm2/s (g/mol)1/3, and MW is the protein molecular weight.
These relationships gave DcCCL21 = 6.5×10−7 cm2/s and DcCXCL12 = 7.45×10−7 cm2/s.
Solutions of the diffusion equations were solved for free triangular FEM mesh points of
maximum spacing, 8 μm and minimum spacing, 16 nm.
As suggested in previous studies [35, 37], the chemokine receptor occupancy (B), defined as
the concentration of receptor with bound chemokine (RC) divided by the concentration of
total receptor on the cell surface (Rmax) was calculated by assuming chemokine-receptor
binding reaches equilibrium:
where Kd is the binding affinity of chemokine and receptor. CCL21 binding affinity for
CCR7 has been measured on CCR7-transfected cells or on human T-cells, with estimates
ranging from 1 nM to 10 nM [38–40] and here we chose to use Kd = 5 nM. The affinity
between CXCR4 and CXCL12 were reported to be 1.8 nM or 4 nM in [41, 42], and 3 nM
was used here. The receptor occupancy gradient was derived as:
2.12 Single-cell migration analysis
To analyze cell migration in the two-well conjoined gel chemotaxis imaging assay and
isolated microsphere chemotaxis imaging assay, individual dendritic cells or T-cells were
tracked for the time window indicated in the text using Image J (NIH, Bethesda, MD). The
chemotactic index (CI) was defined as the displacement of each cell in the direction of the
attractant gradient divided by the total path length it traveled over the observation time [43].
In the conjoined gel chemotaxis assay, an instantaneous chemotactic index (ICI) was
determined for the 20 cells analyzed in the field of view 1 mm away from the interface
between the cell source and attractant source gels. The ICI was defined as the distance
traveled by the T-cell toward the attractant source gel in one increment of observation time
(5 min) divided by the total displacement of the cell in that interval. These single ICI values
were averaged over all time steps to obtain a mean CI for the total 20 cells tracked in each
condition.
In the isolated microsphere chemotaxis assay, ICI values were determined for each cell
analyzed at each time point over a 1 hr time of observation, and these values were recorded
along with the starting position of each cell at that time step. To capture the effect of
differences in the chemoattractant gradient as a function of distance from the bead, the ICIs
were then binned in 25 μm intervals of distance of the cell from the bead and ICI values
within each bin were averaged to capture the mean strength of chemotaxis as a function of
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position in the gradient over the 1 hr analysis time: i.e. we averaged all ICI values collected
for cells 0–25 μm from bead, 25–50 μm away, 50–75 μm away, etc. For cells whose starting
position were beyond 200 μm were binned together and labeled 250 μm.
2.13 Statistical analysis
Measured values are expressed as means ± standard errors (SE). Levels of significance for
comparing average CI and velocity of dendritic cells in conjoined gel assay were calculated
using an unpaired two-tailed t test. Level of significance for comparing mean values of ICI
of T-cell migration in isolated microsphere assay to hypothetical value zero were calculated
using one sample t test. Level of significance for comparing mean values of ICI as a
function of distance to microspheres was calculated using paired t tests. All calculations
were made using GraphPad Prism 5.0.
3. Results
3.1. Chemokine alginate microsphere formulation
To obtain cell-sized alginate particles, we employed a water-in-oil emulsion synthesis
approach we described previously [25, 44] to prepare calcium alginate microspheres: As
depicted in Supplementary Fig. 1, an aqueous alginate solution was emulsified in iso-octane
with lyophilic surfactants, and the alginate emulsion droplets were ionically crosslinked by
the subsequent addition of aqueous calcium chloride. The resulting alginate particles had a
spherical morphology (as seen by brightfield microscopy, not shown) and diameters of
31±12 um in the hydrated state (Fig. 1A), as measured by laser diffraction.
Chemokines are typically small basic proteins and many are known to bind with substantial
affinity to anionic extracellular GAGs [26, 45–47]. We reasoned that the anionic
polysaccharide chains within alginate microspheres could serve as surrogates for native
mammalian proteoglycans and provide multivalent binding sites to support reversible
loading of chemokines by adsorption into pre-synthesized alginate particles. We chose
human CCL21 (12 kDa, net charge +16) as a model chemokine to study the loading and
release of attractants from alginate microspheres, due to its relevance in immune cell
trafficking to lymphatics and lymphoid tissues [48–52] and its known high affinity for
GAGs [53, 54]. As shown in Fig. 1B for the particular case of alginate microspheres
incubated with a 20 μg/ml CCL21 solution, particles rehydrated with concentrated CCL21
solutions rapidly equilibrated with the chemokine, and maximal levels of attractant were
bound within 30 min. This rapid binding equilibration is consistent with prior studies where
ionic adsorption has been utilized to load charged proteins in alginate matrices [55]. Using
90 min incubations of particles with chemokine, as the quantity of protein mixed with
particles was decreased from 50 μg CCL21/mg alginate to less than 10 μg chemokine/mg
polysaccharide, the loading efficiency of CCL21 increased from 55% to greater than 95%
(Fig. 1C). Flow cytometry analysis of alginate microspheres loaded with fluorescently-
labeled CCL21 showed uniform shifts of the entire particle distribution to brighter
fluorescence as increasing quantities of CCL21 were added to a fixed concentration of
particles, indicating that the entire population of microspheres contributed uniformly to
chemokine binding (Fig. 1D). The average attractant loading in individual alginate
microspheres was 16 pg CCL21 per particle (average particle size of 31 μm) for the case of
adding 25 μg CCL21 per mg alginate particles. Scatchard plots of the ratio of bound to
equilibrium free CCL21 vs. bound CCL21 (Fig. 1E) were concave, suggesting negative
cooperativity in the adsorption process. Consistent with this finding, the adsorption data was
fit well by an empirical Freundlich isotherm model (solid line through the data in Fig. 1E)
[56], which captures the binding of an adsorbent to multiple sites in a matrix with
heterogeneous binding energy:
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where C is the free chemokine concentration in the loading solution, y is the concentration
loaded in alginate microspheres, α is the adsorption coefficient (quantifying the adsorption
capacity) and 1/n denotes the adsorption exponent indicating the adsorption intensity. Using
nonlinear regression we obtained α as 1.349 ± 0.2443 ml/mg alginate, 1/n as 0.8577 ±
0.05307 (quality of fit R square = 0.9972). Similar heterogeneous binding site equilibria and
negative cooperativity in binding have been measured for other protein-ionic matrix
adsorption studies [57].
3.2. Kinetics and bioactivity of CCL21 release from alginate microspheres
The kinetics of CCL21 release from alginate microspheres was characterized by bulk
measurements of chemokine in the supernatant of particle suspensions over time. We first
assessed the impact of medium ionic strength on chemokine release. Consistent with
electrostatic-mediated binding of CCL21 to the alginate matrix, increasing the ionic strength
of the release buffer increased the rate of attractant release from the particles (Fig. 2A).
Next, we evaluated the effect of the amount of chemokine loaded on the release rate (Fig.
2B); the net amount of CCL21 released at any time was proportional to the quantity loaded.
We fit the release data over 5 hrs to a model applying Fick’s law to a polydisperse collection
of microspheres with the experimentally-determined size distribution to obtain an effective
diffusion constant for chemokine in the alginate matrix [57]. This model fit the data well
(Fig. 2D) with Deff = (4.73 ± 0.26) × 10−13 cm2/s for particles incubated with 25 μg CCL21/
mg alginate during loading. This experimentally-derived Deff provided the means for
modeling the chemokine gradient formed around individual particles (discussed in detail
below).
We next used a modified Boyden chamber chemotaxis assay [35] to evaluate the bioactivity
of chemokine released from alginate microspheres for attracting resting human T-cells. T-
cells suspended in medium or fibrillar collagen gels were placed on the top surface of 5 μm-
pore membranes, and migration through the filters in response to soluble CCL21 or
equivalent total doses of CCL21 loaded in alginate microspheres in the lower wells was
quantified after 2 hr (for cells in medium) or 4 hr (for cells in collagen). The objective of
these measurements was only to obtain a baseline assessment of whether attractant released
from the microspheres was functional for chemoattraction, since the concentration gradients
produced in this assay by soluble CCL21 are expected to be very different from that
generated by the CCL21-releasing microspheres [20]. As expected [38–40], soluble CCL21
elicited chemotaxis of T-cells when added to the lower well of the migration chambers at
doses of 10 ng/ml, with attraction plateauing at 100 ng/ml or higher concentrations for cells
in medium (Fig. 3A). When cells were added to filters in collagen (requiring migration
through the collagen matrix to cross the filters), lower levels of net migration were detected
but a similar trend of increasing migration with increasing CCL21 dose were observed, with
a plateau in response at 1 μg/ml attractant. Importantly, CCL21-releasing alginate particles
also triggered dose-dependent chemoattraction of T-cells in both medium and collagen gels,
demonstrating activity of the released protein (Fig. 3A). Note that equivalent migration is
not expected here both because of the different gradients generated by soluble attractant vs.
microspheres and also because only 10–15% of the CCL21 is released from the
microspheres over these time courses.
Sustained cell migration through 3D extracellular matrix is more relevant for gauging the
potential utility of alginate microspheres for engineering chemotaxis in vivo than migration
very short distances through filter membranes [58]. Thus, as a second bioactivity assay we
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also measured single-cell migration paths for human dendritic cells (DCs) suspended in
collagen gels and exposed at time zero to an adjacent (physically associated) gel containing
either soluble chemokine or CCL21-loaded alginate microspheres (schematically illustrated
in Fig. 3B). Maturing DCs in the periphery express CCR7 and migrate to lymph nodes in
response to CCL21 produced by lymphatic vessels in the local tissue [6, 59]; we used DCs
stimulated with LPS to trigger CCR7 expression (Supplementary Fig. 2A) for this assay.
5×104 alginate microspheres loaded with a total of 0.8 μg CCL21 (releasing ~0.16 μg over
10 hr) were introduced in the “attractant source” side gel at time zero, and migration of DCs
in the adjacent “cell source” gel and crossing into the adjoining gel were tracked for 10 hr by
videomicroscopy. DCs exposed to microsphere-generated gradients showed highly
directional migration, as seen qualitatively in the video data collected (Supplementary
Videos 1 and 2) and in wind-rose plots of overlaid individual cell paths compared to DCs in
collagen with no attractant present (Fig. 3C). As shown in Fig. 3D, although DCs migrated
with similar velocities in the collagen matrix in the presence or absence of the attractant-
releasing microspheres, the cells migrated with significantly greater directionality toward the
attractant source gel in response to microsphere-generated gradients. Although the release
rate of individual microspheres decays substantially over the timecourse of this assay,
sustained DC attraction was observed throughout the 10 hr observation period. Strikingly,
DCs near the attractant source gel at time zero migrated into the region where alginate
microspheres were deposited and showed strong directional attraction right to the surface of
individual CCL21-releasing particles (visualized by labeling DCs with a red cytosolic dye
and loading the alginate particles with a fraction of Alexa Fluor 488-labeled CCL21, Fig.
3E). Thus, despite the presence of a field of overlapping gradients generated by the large
collection of microspheres in the attractant gel, DCs still sensed and responded to local
gradients around individual nearby microspheres. Altogether, these results suggest CCL21
released from the alginate particles was bioactive and strongly chemotactic for both human
T-cells and dendritic cells.
3.3. Loading and sustained release of homeostatic and inflammatory chemokines from
alginate microspheres
To be generally useful, this chemoattractant delivery approach should be capable of loading/
releasing many different chemokines of interest for targeting different immune cell types.
We thus tested the loading of several other host-derived attractant molecules in alginate
microspheres, including CCL19, CXCL12, and CXCL10. CCL19, a second homeostatic
ligand for CCR7, is expressed in lymph nodes [60, 61], and has a non-redundant role in
lymphocyte homing [62]. CXCL12 is a lymphoid chemokine that attract T-cells, B-cells,
and other immune cells [63], and CXCL10 is an IFN-γ-induced chemokine highly expressed
at inflammatory sites, which attracts activated effector T-cells to sites of infection [64, 65].
As summarized in Table 1, these attractants have similar molecular weights, but differ in
their net charge and net surface-exposed charge. For comparison with CCL21 loading/
release from alginate particles, we measured the loading efficiency for two different
attractant loading concentrations (Fig. 4A), and then measured release into serum-containing
medium over time (Fig. 4B). The hierarchy of chemokine loading into the alginate particles
was inverse to the release rate: CXCL12 loaded to the highest levels in the particles but also
released extremely slowly from the particles. Although this remains a limited dataset, we
found that for these four chemokines, the logarithm of the effective diffusivity of each
chemokine in alginate (obtained by fitting the release data to a Fick’s law model as in Fig.
2D) correlated well with the net surface charge of the proteins per residue (Fig. 4C),
consistent with charge-mediated interactions between the attractants and alginate matrix
dominating the loading/release behavior. These data suggest that alginate particles may be
useful for engineering attractant gradients with a range of different candidate chemokines,
though attractants with a very high surface charge density (e.g., CXCL12) may be bound too
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tightly for effective gradient generation when loading into unmodified, highly charged
alginate.
3.4. Chemotaxis responses to isolated chemokine-releasing microspheres
The experiments shown in Fig. 3B-E are a useful in vitro model of chemoattraction of cells
to a site of particle deposition in tissue, as might be used in immunotherapy or vaccination.
However, the striking local attraction of DCs to individual microspheres observed in these
experiments prompted us to examine more closely the chemoattraction elicited by isolated
individual microspheres, as a model for the response of leukocytes to isolated
chemoattractant-releasing cells acting as a point source of chemokine. To this end, we first
sought to measure and/or predict the concentration profiles of attractant generated around
individual alginate microspheres loaded with CCL21. We first tried to directly visualize
gradients around individual particles in collagen gels using fluorescently-labeled CCL21 as
a tracer, but the minimum concentration of Alexa dye-labeled CCL21 that could be detected
above background by either our widefield or confocal microscope systems was ~200 ng/ml,
well above the concentration for chemotaxis observed in our collagen migration assays (data
not shown). Thus, we instead used bulk measurements of chemokine release rates from
collections of beads in suspension to model and predict the gradient expected around
individual microspheres in collagen.
We simulated concentration fields evolving around individual microspheres using a 2D axis-
symmetric model in which a microsphere was embedded in an 500 μm space (modeling
alginate particles suspended in collagen at a concentration of 1×104 microspheres/ml); the
chemokine was given an effective diffusivity in the alginate matrix Deff as determined from
our experimental bulk release data (e.g., Fig. 2D), while the diffusivity of chemokine in
fibrillar collagen was taken as half its diffusivity in water [35, 36] (see Methods). From the
chemokine concentration profiles, we also calculated the receptor occupancy gradient for
cells located at any position along the chemokine gradient, as it the receptor occupancy
gradient that determines signaling and directional migration [66].
The predicted concentration profiles and receptor occupancy gradients over time and space
for a 50 μm diameter alginate particle initially loaded with 40 fg CCL21 (mimicking the
loading achieved for incubations of 25 μg CCL21 per mg alginate) are plotted in Figs. 5A
and 5B. The rapid diffusion of released CCL21 [35, 36] quickly dispersed chemokine
throughout the simulation volume (Fig. 5A), while the decaying rate of chemokine release
from microspheres over time led to chemokine concentration gradients (and thereby receptor
occupancy gradients) that slowly decayed over the simulated timecourse (Fig. 5B). Prior
studies [37, 67] have shown that leukocytes can sense and orient in response to a 2% change
in chemokine concentration across the cell body (~10 μm) at optimal concentrations near Kd,
and the threshold receptor occupancy difference for robust chemotactic migration has been
estimated to be ~10 receptors across the length of a cell. This corresponds to a 0.033 – 0.1%
change in receptor occupancy across the cell body for a lymphocyte expressing 10, 000 – 30,
000 chemokine receptors. Comparing the predicted receptor occupancy gradient to this
threshold (expressed by the gray shaded area as a range covering physiological receptor
expression levels, Fig. 5B), we see that over the first few hours the microsphere-generated
gradient provides a detectable chemotactic stimulus for cells more than 150–200 μm away
from the source. The model also predicts that by 5 hours, although the gradient has decayed
at longer distances, a functional chemotactic gradient remains at distances 75–125 μm or
less from the source. For comparison, we also modeled the concentration profile and
receptor occupancy gradient evolution for CXCL12-releasing particles. For the same
attractant loading conditions modeled above (25 μg CXCL12/mg alginate), the
concentration gradient of CXCL12 (Fig. 5C) developing around an individual microsphere
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was very shallow (less than 1% per 10 μm). Further, the receptor occupancy gradient was
only beyond the estimated threshold within 50 μm of the microsphere surface (Fig. 5D).
To test whether this simple analysis of chemokine receptor engagement could accurately
predict lymphocyte migration responses to chemokine-releasing microspheres, we imaged
the response of activated T-cells to isolated CCL21- or CXCL12-releasing alginate
microspheres in collagen gels, using experimental conditions matching as closely as possible
the modeled conditions. Human T-cells were activated with PHA and IL-2; these cells
expressed both CXCR4 and CCR7 (Supplementary Fig. 2B, C). As shown in Fig. 5E,
activated T-cells suspended in collagen gels with CCL21-releasing alginate particles were
attracted to individual microspheres from up to nearly 200 μm away. In the first hour, the
mean chemotactic index (averaged values of the displacement of a given cell over a 1 min
time interval toward the nearest particle divided by the total displacement) was on average
greater than zero (indicating migration toward the nearest bead) for cells 150 μm or closer to
attractant beads, and increased monotonically as the distance from the cell to nearest bead
source decreased. After 4 hours, a similar trend of increasing chemotactic index with
decreasing distance to the nearest bead held, but cells greater than 125 μm from the nearest
bead exhibited a mean ICI which was not statistically different from zero. Thus, in line with
the predictions from the simulation, the strength of the attractant gradient decayed and
contracted around the microsphere over this 5-hr timecourse. By contrast, CXCL12-
releasing alginate microspheres showed much weaker chemoattraction of T-cells, with some
chemotaxis detected in the first hour, but no attraction by the second hour of observation
(Fig. 5F). Thus, the simulations correctly captured the chemotaxis response of T-cells
responding to CCL21-releasing particles, but did not predict the behavior of cells migrating
near CXCL12-releasing microspheres. This outcome likely reflects the reductionist nature of
the model employed here, which neglected receptor internalization and other modes of
receptor desensitization that could be important for CXCL12-CXCR4 signaling.
4. Discussion
Chemokines control lymphocyte trafficking in health and disease, and are interesting
candidates for therapeutic manipulation in vaccines and cancer immunotherapy. We
previously showed that chemokines encapsulated in PLGA particles could create more
sustainable and in some cases steeper chemoattractant concentration gradients within ECM
gel models of tissue matrix compared to bolus soluble chemokine injections [20]. Here we
sought to develop a more facile microsphere release system with greater control over the
range of chemokines that could be functionally encapsulated and the dosages of attractant
that could be loaded. We found the physical and chemical properties of alginate hydrogels
particularly attractive in this setting: (i) The high hydrophilicity provides an environment
that will preserve the bioactivity of encapsulated molecules; (ii) alginates form hydrogels
under very mild gelation conditions permitting in situ loading of biomolecules if desired
[68]; (iii) alginate has been used to carry cells and cytokines for therapeutic use due to its
advantages of biocompatibility and mild processing conditions [68, 69]; and finally (iv) the
anionic polysaccharide structure acts as a surrogate of extracellular GAGs to mimic
reversible chemoattractant binding to the ECM.
Based on these considerations, we developed a post-synthesis adsorption approach to load
chemoattractants into alginate microspheres, which provided several advantages over
seeking to entrap chemokines during the particle preparation: Small single-use batches of
attractant-loaded particles could be prepared, allowing efficient use of recombinant proteins;
the attractants were not exposed to high shear or organic solvents used in the particle
preparation; and a single homogeneous preparation of microspheres could be used for many
independent experiments. Testing several different human chemokines, we found that these
Wang and Irvine Page 12
Biomaterials. Author manuscript; available in PMC 2012 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
basic proteins could be loaded to high levels in alginate particles, with release rates
predicted by their net surface charge. Overall, loading/release measurements were consistent
with a dominant role for electrostatics in mediating binding of the chemokines studied here
to the alginate matrix, similar to binding of these largely cationic factors to GAGs in native
ECM.
Cellular secretion rates for chemokines have been measured to range from 10−8 to 10−6 ng/
hr/cell [70, 71]. However, these measurements are usually based on bulk measurements
taken after prolonged culture periods of 24 or 48 hrs; while some chemokines are
constitutively secreted, others are produced rapidly after stimulation within a brief time
window (15 min – 1 hr) [72] and so these in vitro measurements may underestimate the
production rate of chemokines. The maximum rates of cytokine secretion fall in the range of
2300–8000 molecules/cell·s [73] (estimated to be 1.65–5.74×10−4 ng/cell·hr for CCL21).
Here we found that alginate microspheres loaded with the human chemokines CCL21,
CCL19, CXCL12 and CXCL10 released these attractants at rates ranging from 7.2×10−6 –
3.2×10−3 ng/hr/paritcle, covering the physiological range of chemokine release by
individual cells. For CCL21, CCL19, and CXCL10, release rates in the physiological range
were maintained for at least 24 hrs (data not shown).
We used modified Boyden chamber assays and direct videomicroscopy analysis of cells
migrating in collagen to assess the bioactivity of alginate-released chemokines, and found in
both assays evidence of potent chemoattraction elicited by particle-released chemokine. The
striking attraction of dendritic cells to individual alginate microspheres in the conjoined gel
assay prompted us to explore in more detail cell migration near individual cell-sized
attractant sources. The ability to experimentally define (and manipulate) the attractant
release rate from these microspheres provides the opportunity to dissect how immune cells
interpret local attractant gradients in a manner that would be challenging to achieve using
live cells as chemokine sources. We analyzed the migration response of activated T-cells
toward microspheres releasing CCL21 or CXCL12, as these two attractants were
distinguished by moderate and very slow release kinetics, respectively. Because direct
visualization of chemokine gradients proved to be problematic, we used measurements of
chemokine release coupled with careful characterization of the microsphere size distribution
(because particle size influences the rate of chemokine freed at the particle surfaces) to
provide experimental data guiding simulations of attractant gradient evolution around
isolated microparticles. The modeling semi-quantitatively predicted the responsiveness of T-
cells to CCL21-releasing microspheres, with the chemoattracting “reach” of the
microspheres initially drawing in cells from nearly 200 μm away, but collapsing toward the
source particle slowly over the course of hours. By contrast, T-cell migration toward
CXCL12-releasing microspheres was transient, with chemotaxis of cells up to 125 μm away
at the start of the experiment but no attraction detected after 1 hr. The simple diffusion-
based modeling of the CXCL12 gradient predicted that some attraction should have been
sustained near the beads. The good agreement of responses seen for CCL21 and relative lack
of agreement for the model with CXCL12 migration data likely reflects the key difference in
receptor biology for these two ligands; CCL21 bound to CCR7 does not trigger receptor
downregulation or desensitization [74, 75], while CXCL12 triggers rapid receptor
internalization [76, 77]. The loss of receptors from the cell surface raises the effective
threshold in receptor occupancy that must be met for directional migration, likely ablating
chemotaxis for cells in CXCL12 gradients over time.
For some applications, it would be desirable to modulate the release rate of individual
chemokines independent of the quantity of attractant loaded. Several strategies could
provide this level of control: (i) varying the density of alginate or calcium content in the
hydrogel microspheres [78]; (ii) adding additives that alter protein binding [30]; or (iii)
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derivatizing carboxyl functional groups on the alginate chains to alternate functional groups
that could exhibit enhanced or reduced binding [79]. The flexibility of tuning release
properties of chemokines from alginate microspheres would make it a further attractive
method of delivery chemokines for therapeutic use and chemotaxis studies.
5. Conclusions
The development of versatile chemoattractant carrier systems is of interest for both
therapeutic applications and fundamental chemotaxis studies. Here we have shown that
alginate hydrogel microspheres can be efficiently loaded with a range of different
chemokines and release bioactive protein generating functional attractant gradients both in
2D medium and 3D collagen ECM gels. We have also demonstrated the use of chemokine
loaded alginate microspheres as model attractant “point sources” to investigate the
chemotaxis behavior of activated human T-cells and showed that a simple diffusion-based
modeling of the concentration profile and resulting receptor occupancy gradient could
predict chemotactic behavior for an attractant receptor which does not undergo
internalization/desensitization. We thus believe that this alginate hydrogel microsphere
system could be useful in in vitro and in vivo chemotaxis studies, and possibly in
immunotherapy and vaccine delivery by attracting target effector cells to desired tissue sites.
More generally, attractants involved in developmental, wound healing, and tissue
regeneration processes could be delivered using this approach to engineer chemotaxis of
many cell types in vitro and in vivo.
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Fig. 1. Characterization of alginate hydrogel microspheres and chemokine loading
(A) Size distribution of alginate particles determined by laser diffraction. (B) The net
amount of chemokine bound and percentage of added chemokine adsorbed by alginate
microspheres (loading efficiency) were quantified as a function of incubation time for 5×106
particles/ml incubated with 20 μg/ml CCL21 (equivalent to 0.4 μg CCL21/mg alginate) up
to 24 hrs. (C) Loading efficiency and net quantity of CCL21 loaded into alginate
microspheres incubated for 90 min with varying doses of chemokine. (D) Flow cytometry
analysis of microspheres showing binding of Alexa fluor 555-labeled CCL21 to particles
following incubation of microspheres with indicated Alexa 555-CCL21 doses for 90 min.
(E) Scatchard plot of CCL21 adsorption to alginate microspheres. Data were fit to the
Freundlich model for adsorption (solid line). Data shown are means ± SE.
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Fig. 2. Kinetics of CCL21 release from alginate microspheres
(A) Impact of medium ionic strength on rate of CCL21 release from alginate particles
(particles loaded at 25 μg CCL21/mg alginate for 90 min) incubated in 10 mM PBS pH 7.4,
2 mM CaCl2, 1% BSA medium containing the indicated concentrations of NaCl at 37°C. (B)
Kinetics of CCL21 release from alginate particles into RPMI medium with 10% FCS at
37°C as a function of quantity of chemokine added to alginate during loading. (C) Fractional
release of CCL21 vs. time fit to a simple diffusion model (solid line), for particles incubated
with 25 μg CCL21/mg alginate during loading. Data shown are means ± SE.
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Fig. 3. Bioactivity of CCL21 released from alginate microspheres
(A) Percentage of resting human T-cells migrating through filters in response to different
total doses of CCL21 provided in soluble or microsphere form in a modified Boyden
chamber chemotaxis assay; incubations were carried out for 2 hr (cells applied to filter
plates in medium) or 4 hr (cells applied to filter plates in collagen gels). Open bars, soluble
CCL21 with cells in medium; black bars, soluble CCL21 with cells in collagen; gray bars,
microspheres with CCL21 and cells in medium; hatched bars, microspheres with CCL21 and
cells in collagen. (B)–(E) Conjoined collagen gel chemotaxis assay with LPS-activated
human dendritic cells in a “cell source” gel migrating toward an “attractant source” gel
loaded at time zero with 0.8 μg CCL21 in 5×104 alginate microspheres or control gels
lacking attractant. (B) Schematic of conjoined gel assay setup; scale bar is 2 mm. (C) Wind-
rose 2D plots of individual DC migration paths tracked 3–6 hr after start of the assay, for
cells located 1 mm from the center of the conjoined gel; each track length is 60 min; x-y
axes are cell displacements from their starting position at the beginning of the time interval
in μm. (D) Average chemotactic index (open bars) and velocity of DCs (filled bars) (n = 20
cells analyzed for each condition; unpaired t test: *** P<0.0001). (E) Migrating DCs (red)
entering the “attractant source” gel migrated directly into contact with individual CCL21
alginate microspheres (marked by Alexa-fluor-tagged CCL21, green); Lower panels show
zoomed-in view of individual microsphere highlighted by the dashed box in upper panel
series; scale bar is 50 μm.
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Fig. 4. Loading and release of CXCL12, CCL19 and CXCL10 from alginate microspheres
(A) Loading efficiency of chemokines in microspheres was measured following incubation
of 2.5 or 25 μg chemokine/mg alginate for 90 min. (B) Kinetics of chemokine release into
serum-containing medium at 37°C for particles incubated with 25 μg chemokine/mg alginate
during loading. (C) Logarithm of effective diffusivity of chemokines in alginate as a
function of net surface charge per residue, with best fit linear regression. Data shown are
mean ± SE.
Wang and Irvine Page 22
Biomaterials. Author manuscript; available in PMC 2012 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 5. Relationship between microsphere-generated chemoattractant gradients, receptor
occupancy, and migration responses
(A–D) Simulated chemokine concentration gradients developed around an isolated 50 μm-
diameter alginate microsphere releasing CCL21 (A, B) or CXCL12 (C, D), calculated from
experimentally-determined release rates of particles incubated with 25 μg chemokine/mg
alginate during loading. Shown are the chemoattractant concentration (C) (A, C) and
chemokine receptor occupancy gradients (dB/dr) as a function of distance to the surface of
microsphere (r) (B, D) at 15 min, 0.5 hr, 1 hr, 2 hr, 3 hr, and 5 hr; arrows indicate the trend
of increasing time. Shaded areas in B, D indicate the estimated threshold of gradients in
receptor occupancy required for directional migration for cells expressing 10, 000 to 30, 000
receptors. (E, F) Mean chemotactic index (CI) of activated human T-cells migrating through
collagen gels in the vicinity of isolated microspheres releasing CCL21 (E) or CXCL12 (F)
as a function of distance from the microspheres (r); shown are mean CI ± SE determined
from 1-min time steps of cells analyzed in the indicated window of time after start of the
experiment; dashed lines indicate the expected CI for random migration (zero); values
significantly different from zero are indicated: * P<0.5, ** P<0.001, *** P<0.0001. CIs
determined for (E) n = 107 cells (0–1 hr) and n = 45 cells (4–5 hr); * P<0.05; (F) n = 67
cells (0–1 hr) and n = 59 cells (2–3 hr); * P<0.05.
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Table 1
Chemokine physicochemical properties
CXCL12 CCL21 CCL19 CXCL10
Molecular weight (kDa) 7.96 12.25 8.80 8.70
Net charge +9 +16 +7 +9
Isoelectric point 10.3 10.5 10.1 10.5
Surface positive charge +13 +25 +13 +13
Surface negative charge 0 −9 −6 −5
Net surface charge per residue 0.19 0.14 0.09 0.10
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